Sandoz unveils global action plan to improve access to biosimilars

As the spot­light trains on ac­cess to biosim­i­lars, No­var­tis’ gener­ics unit on Thurs­day re­leased a glob­al ac­tion plan to boost biosim­i­lar adop­tion by 2030.

The ac­tion plan is part of the Act4Biosim­i­lars ini­tia­tive launched by San­doz last year and led by a steer­ing com­mit­tee of pa­tient ad­vo­cates, health­care pro­fes­sion­als and oth­er ex­perts. The plan in­cludes rec­om­men­da­tions for stream­lin­ing the reg­u­la­to­ry process, dri­ving pa­tient aware­ness and fight­ing mis­in­for­ma­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN